Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.
Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Acti...
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28...
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed o...
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026
Novo Nordisk A/S's job cuts and profit outlook reset reflect a strategic pivot to margin discipline, not long-term weakness, amid evolving GLP-1 market dynamics. Despite near-term margin pressure a...
Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm
Novo Nordisk A/S announced this morning that it will cut ~9k staff and that the one-off costs of doing so will severely impact profitability in 2025. Novo Nordisk's 2025 has been turbulent, but I b...
Ozempic Parent Announces 9,000 Job Cuts in Restructuring Plan
Pharmaceutical name Novo Nordisk A/S (NYSE:NVO), the maker of weight-loss drugs Wegovy and Ozempic, is in the spotlight today after announcing roughly 9,000 job cuts and slashing its full-year guid...
Novo Nordisk Cuts 9,000 Jobs and Slashes Guidance. Why the Stock Is Rising.
The weight-loss drugs giant also slashed its profit guidance for the second time in six weeks.
Weight-loss drug manufacturer Novo Nordisk cuts 9000 jobs — and its profit forecast
New CEO Mike Doustdar is kitchen-sinking the costs of restructuring the company to focus on diabetes and anti-obesity drugs.
Novo Nordisk cuts 9K jobs to save $1.26B amid Wegovy growth, Eli Lilly rivalry
Novo Nordisk, the Danish pharmaceutical giant behind the obesity drug Wegovy, said on Wednesday it will cut about 9,000 jobs globally in a major restructuring effort, aiming to save 8 billion Danis...
Novo Nordisk to cut 9,000 jobs in major restructuring drive
Novo Nordisk (NYSE:NVO) has announced plans to reduce its global workforce by around 9,000 roles, roughly 12% of its 78,400 employees, as part of a wide-ranging company overhaul aimed at sharpening...
Wegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
The company, which is also known for its Ozempic diabetes treatment, already said in August that it had implemented a global hiring freeze covering job roles that were not critical for its business.
Novo Nordisk to cut 9,000 jobs in restructuring
Wegovy-maker Novo Nordisk will cut 9,000 jobs in a restructuring, aiming to save 8 billion Danish crowns ($1.26 billion) annually, the company said on Wednesday, as it battles rising pressure from ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Related Companies